Quick Answer
Lyra Therapeutics, Inc. reported Research And Development Expense of $18.41 million for the year ending 2025.
- Lyra Therapeutics, Inc. showed a decrease of -57.9% in Research And Development Expense from 2024 to 2025.
- This data is from Lyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Lyra Therapeutics, Inc.'s Research And Development Expense has grown by 53.0%.
- Historical annual values: Fiscal year 2025: $18.41 million | Fiscal year 2024: $43.77 million | Fiscal year 2023: $48.03 million | Fiscal year 2022: $38.80 million | Fiscal year 2021: $29.69 million | Fiscal year 2020: $12.52 million | Fiscal year 2019: $12.03 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: